169 related articles for article (PubMed ID: 28134499)
1. Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study.
Khalafallah AA; Slancar M; Cosolo W; Abdi E; Chern B; Woodfield RJ; Copeman MC
Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12638. PubMed ID: 28134499
[TBL] [Abstract][Full Text] [Related]
2. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
Van den Wyngaert T; Delforge M; Doyen C; Duck L; Wouters K; Delabaye I; Wouters C; Wildiers H
Support Care Cancer; 2013 Dec; 21(12):3483-90. PubMed ID: 23955094
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
[TBL] [Abstract][Full Text] [Related]
4. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Coleman R; Woodward E; Brown J; Cameron D; Bell R; Dodwell D; Keane M; Gil M; Davies C; Burkinshaw R; Houston SJ; Grieve RJ; Barrett-Lee PJ; Thorpe H
Breast Cancer Res Treat; 2011 Jun; 127(2):429-38. PubMed ID: 21394500
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henk H; Teitelbaum A; Kaura S
Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
[TBL] [Abstract][Full Text] [Related]
6. Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Wu EQ; Bensimon AG; Marynchenko M; Namjoshi M; Guo A; Yu AP; Ericson SG; Raje N
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):326-35. PubMed ID: 21700528
[TBL] [Abstract][Full Text] [Related]
7. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
[TBL] [Abstract][Full Text] [Related]
8. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid.
Coleman R; Burkinshaw R; Winter M; Neville-Webbe H; Lester J; Woodward E; Brown J
Expert Opin Drug Saf; 2011 Jan; 10(1):133-45. PubMed ID: 21114419
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Amadori D; Aglietta M; Alessi B; Gianni L; Ibrahim T; Farina G; Gaion F; Bertoldo F; Santini D; Rondena R; Bogani P; Ripamonti CI
Lancet Oncol; 2013 Jun; 14(7):663-70. PubMed ID: 23684411
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
[TBL] [Abstract][Full Text] [Related]
14. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G
J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195
[TBL] [Abstract][Full Text] [Related]
15. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
16. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
18. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Berenson JR; Yellin O; Crowley J; Makary A; Gravenor DS; Yang HH; Upadhyaya GH; Flinn IW; Staszewski H; Tiffany NM; Sanani S; Farber CM; Morganstein N; Bolejack V; Nassir Y; Hilger JD; Sefaradi A; Shamouelian A; Swift RA
Am J Hematol; 2011 Jan; 86(1):25-30. PubMed ID: 21120861
[TBL] [Abstract][Full Text] [Related]
20. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
